APLS vs CCI · rev $781.4M vs P/E 40, rev $6.57B
Apellis Pharmaceuticals Inc (APLS) versus Crown Castle (CCI) — a side-by-side from cached financials, not a winner call.
Apellis Pharmaceuticals Inc (APLS) is a biotechnology company listed on US.
Crown Castle (CCI) is a reit - specialty company listed on US.
Latest reported APLS revenue for 2024-12-31 was $781.4M. Net income was -$197.9M. Revenue was up 97.0% from 2023-12-31 to 2024-12-31. APLS currently screens at market cap $2.29B.
Latest reported CCI revenue for 2024-12-31 was $6.57B. Net income was -$3.90B. Revenue was down 5.9% from 2023-12-31 to 2024-12-31. CCI currently screens at market cap $40.93B and trailing P/E 39.6.
APLS currently screens at market cap $2.29B. CCI currently screens at market cap $40.93B and trailing P/E 39.6.
Not investment advice. Open the APLS and CCI stock pages for the full models.
Not investment advice.